GlassScriptPhysician profile
Bradley Bilbro
NPI 1659893337
$4,293.17
in general payments reported to CMS, 2019-2025
43 companies · $973 in 2025
The $973 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.92 · 2020: $221 · 2021: $187 · 2022: $597 · 2023: $816 · 2024: $1,426 · 2025: $973.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,201 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,201.02 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $968.80 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $466.15 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $346.81 | 2020-2025 | Farxiga, Airsupra |
| Pfizer INC. | $335.68 | 2020-2025 | |
| Amgen INC. | $289.14 | 2020-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $263.29 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $255.89 | 2019-2025 | Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.70 | 2021-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.71 | 2022-2024 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $85.09 | 2020-2024 | Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $82.91 | 2024-2025 | Rexulti |
| Lundbeck LLC | $82.80 | 2023-2025 | Rexulti, Vyepti |
| Exact Sciences Corporation | $75.95 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $62.70 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.58 | 2023-2025 | Caplyta |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Bilbro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.